Lexaria Bioscience begins dosing for GLP-1 study #4

Lexaria Bioscience (LEXX) has begun dosing in the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4. The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs. The Study arms are as follows: Arm 1 – DehydraTECH-CBD capsules; Arm 2 – DehydraTECH-semaglutide capsules; Arm 3 – DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules; Arm 4 – Rybelsus tablets; Arm 5 – DehydraTECH-tirzepatide capsules. Quality control release testing of the clinical test articles has now been completed. The Study is planned to be conducted using seven clinical investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. The Study, upon completion, is expected to be regarded as the equivalent of a Phase 1b registrational study by the U.S. Food and Drug Administration